The S&P 500 may be due for a short-term bounce after its pullback from last week's record highs — but don't expect it to last ...

In a report released today, Ryan Zimmerman from BTIG maintained a Hold rating on Integra Lifesciences (IART – Research Report). The company’s ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Orthofix (OFIX – Research Report) today. The company’s shares opened today at ...

BTIG downgraded General Dynamics Corporation (NYSE:GD)to Neutral given the ongoing regulatory hurdles and supply chain ...

Apollo Commercial Real Estate Finance (NYSE:ARI), currently trading at $9.09 with a market capitalization of $1.26 billion, maintained a Neutral stock rating from BTIG following the company's ...

Investing.com -- BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth. The brokerage noted ...

For more information about the conference, email [email protected]. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a BTIG representative ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged out to their BTIG representative or contact the electroCore investor relations team at [email protected].

NEW YORK--(BUSINESS WIRE)--BTIG announced today that it will host its annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Tuesday, February 11 through Wednesday ...

BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth.